Single-cell sequencing reveals distinct peripheral immune responses in anti-MDA5 antibody positive dermatomyositis with rapidly progressive interstitial lung disease

单细胞测序揭示了抗MDA5抗体阳性皮肌炎伴快速进展性间质性肺疾病中独特的周围免疫反应。

阅读:1

Abstract

BACKGROUND: Anti-melanoma differentiation-associated protein 5 antibody positive dermatomyositis (MDA5(+) DM) is an autoimmune disease related to rapidly progressive interstitial lung disease (RPILD) with high mortality. However, the pathogenesis of MDA5(+) DM with RPILD remains unclear. We aimed to explore the peripheral immune landscape of MDA5(+) DM with RPILD using single-cell RNA sequencing (scRNA-seq). METHODS: We performed scRNA-seq of peripheral blood mononuclear cells (PBMCs) from MDA5(+) DM with RPILD (n = 4), MDA5(+) DM with ILD (non-RPILD, n = 3), and healthy controls (HCs, n = 3). RESULTS: The proportion of CD14(+) monocytes increased, but the proportion of natural killer cells, CD4(+) T cells and CD8(+) T cells decreased in MDA5(+) DM with RPILD compared with HCs. Obvious antiviral response was the main feature of MDA5(+) DM with RPILD, and the expression of several interferon-stimulated genes (ISGs) related to RIG-I pathway increased, including IRF7, DDX60, IFI27 and IFI6. However, this antiviral response was not significant in MDA5(+) DM with ILD. In addition, multiple immune pathways were downregulated in MDA5(+) DM with RPILD, including antigen processing and presentation, translation initiation, mRNA splicing, and activation of T and B cells. Cell communication analysis revealed that multiple signaling pathways, including MHC-I and MHC-II, were attenuated in MDA5(+) DM with RPILD. Notably, MHC-II signaling was absent in CD4(+) naïve T cells from MDA5(+) DM with RPILD. CONCLUSIONS: This study demonstrates that antiviral response plays an important role in the pathogenesis of MDA5(+) DM with RPILD, as well as changes in downstream immune pathways, providing potential therapeutic targets for future treatment.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。